[Management of antithrombotic therapy in patients with bleeding after percutaneous coronary intervention]

Area of Science:

• Cardiology
• Interventional Cardiology
• Pharmacology

Background:

• Bleeding is a common complication following percutaneous coronary intervention (PCI).
• Patients often receive dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 inhibitor, or DAPT plus anticoagulation for conditions like atrial fibrillation.
• Balancing bleeding risk against thrombotic risk during antithrombotic therapy management post-PCI is complex.

Purpose of the Study:

• To discuss management strategies for antithrombotic therapy in patients experiencing bleeding after PCI.
• To review European guidelines and consensus documents for managing bleeding complications.
• To provide insights into balancing antithrombotic therapy risks and benefits in this patient population.

Main Methods:

• Review of existing European consensus documents and guidelines.
• Discussion of antithrombotic therapy management based on bleeding severity.
• Analysis of the interplay between bleeding risk and thrombotic risk.

Main Results:

• Currently, no dedicated studies exist for managing post-PCI bleeding.
• Management relies on consensus documents that offer suggestions based on bleeding severity.
• Strategies involve adjusting antiplatelet and/or anticoagulant therapy.

Conclusions:

• Effective management of post-PCI bleeding requires careful consideration of antithrombotic therapy.
• Consensus-based recommendations guide clinical decisions in the absence of dedicated trial data.
• Individualized patient assessment is crucial to balance antithrombotic therapy risks.